Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma

Annals of Hematology

Volumn 89, Issue 4, 2010, Pages 391-397

  Kim, Jeong Eun ^a   Yoo, Changhoon ^a   Lee, Dae Ho ^a   Kim, Sang We ^a   Lee, Jung Shin ^a   Suh, Ceolwon ^a  

^a University of Ulsan   (South Korea)

Author keywords

Multiple myeloma; Prognostic factor; Serum albumin level

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; HEMOGLOBIN; M PROTEIN; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SOUTH KOREA; ADOLESCENT; AGED; AUTOTRANSPLANTATION; BLOOD; MIDDLE AGED; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77649329582     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0841-4     Document Type: Article

References (20)

1. The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749-757
2. Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36:1192-1201
3. Bataille R, Durie BG, Grenier J (1983) Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 55:439-447
4. Bataille R, Durie BG, Grenier J, Sany J (1986) Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 4:80-87
5. Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008-2011
6. Bjerrum OW, Plesner T (1985) Beta-2-microglobulin: a valuable parameter of stage, prognosis and response to treatment in myelomatosis. Scand J Haematol 35:22-25
7. Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC (1990) Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol 75:506-510
8. Dawson AA, Ogston D (1971) Factors influencing the prognosis in myelomatosis. Postgrad Med J 47:635-638
9. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854
10. Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA (1990) Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 75:823-830
11. Ershler WB, Keller ET (2000) Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51:245-270
12. Fonseca R, San Miguel J (2007) Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 21:1115-1140
13. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420
14. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441-450
15. Kapoor P, Snozek CLH, Colby C, Larson DR, Katzmann JA, Rajkumar SV, Greipp PR (2008) Clinical impact of discordance in serum albumin measurements on myeloma international staging system. J Clin Oncol 26:4051-4052
16. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248-255
17. Matzner Y, Benbassat J, Polliack A (1978) Prognostic factors in multiple myeloma: a retrospective study using conventional statistical methods and a computer program. Acta Haematol 60:257-268
18. Mihou D, Katodritou E, Zervas K (2007) Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: The role of albumin in the model. Hematology 12 (6):527-531
19. Salive ME, Cornoni-Huntley J, Phillips CL, Guralnik JM, Cohen HJ, Ostfeld AM, Wallace RB (1992) Serum albumin in older persons: relationship with age and health status. J Clin Epidemiol 45:213-221
20. Sullivan DH (2001) Guest editorial: what do the serum proteins tell us about our elderly patients? J Gerontol A Biol Sci Med Sci 56:M71-74